Myopia

NVK002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for patients ages 3 to 17.

Instrumentation recreates properties of the myopic eye to test lenses that prevent visual decline.

Growing evidence supports dual therapy to slow progression.

An epidemiologic study of myopia in a Chinese province found that economic status, gender, and age were associated with rates of myopia.

Currently, there are several novel spectacle designs available across the world. Unfortunately, none of them are available in the US currently.

Although the use of atropine is not necessarily novel in the myopia management world, the fact that practitioners may soon have an FDA approved formulation of atropine is new and exciting.

New research suggests sleep is an additional risk factor affecting myopia onset and progression.

In a sham device-controlled, randomized, double-blind clinical trial in China, researchers utilized a device that emits 650 nm red light directly to the retina.

The 20-20-20 rule has taken on a life of its own, but it remains a useful trick to reduce digital eye strain.

Andrew Pucker, OD, MS, PhD, FAAO, and George Magrath, MD, discuss Lexitas Pharma Services' work on modification of the National Eye Institute's corneal fluorescein staining scale.

Mark Bullimore, PhD, MCOptom, shares a brief overview of her presentation on myopia management by slowing progression with low concentration atropine.

Positive 42-month Cypress axial length and cSER outcomes, presented at ARVO in New Orleans, reinforce myopia control safety and efficacy of Diffusion Optics Technology™ spectacle lenses.

Although the 20-20-20 rule is still a solid recommendation, recent studies have provided practitioners with more specific recommendations to help potentially prevent the onset and slow the progression of myopia.

The technology will be shared at the International Congress of Ophthalmology and Optometry China (COOC) conference in Shanghai April 14-16, 2023.

Atropine 0.01% eye drops decreased myopia progression in children over the study course of 1 year.

A look back on what happened in optometry during the week of March 20-March 24.

Researchers retrospectively analyzed the longitudinal clinical data of 117 eyes of 106 Caucasian patients with high myopia MNV treated with intravitreal bevacizumab injections.

Ashley Wallace-Tucker, OD, FAAO, FSLS, Dipl ABO, shares key takeaways from her SECO 2023 panel discussion, "Myopia management."

Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key takeaways from his SECO 2023 presentation, "Drugs of the future."

Danica Marrelli, OD, FAAO, shares key highlights from her presentation, which she presented during the Glaucoma 360 meeting held this year in San Francisco.

Second global virtual event on myopia management scheduled for February 16, 2023.

As our dependence on technology progresses, we have seen tremendous impact on all aspects of our lives—including our kids’ eyes and vision.

Three experts in myopia control convened at the Optometry Times EyeCon meeting to discuss methods to control this burgeoning global epidemic.

Research indicates that too much technology usage results in negative effects on eyesight.

Enhanced treatments, tools, and resources make a difference.